Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Today in Science.
Press releases published on May 14, 2025
NewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare Conference
GlobeNewswire
·
May 14, 2025
NAARDEN, The Netherlands and MIAMI, May 14, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at …
KALA BIO Reports First Quarter 2025 Financial Results and Provides Corporate Update
GlobeNewswire
·
May 14, 2025
-- Ongoing patient enrollment in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED); topline data anticipated in 3Q 2025 -- -- Cash resources of $42.2 million as of March 31, 2025, expected to fund operations into 1Q 2026 -- …
Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
GlobeNewswire
·
May 14, 2025
BRISBANE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate …
New Episode Now Streaming on Alpha Liquid Podcast, Bittensor, Decentralizing Artificial Intelligence
GlobeNewswire
·
May 14, 2025
Miami, FL, May 14, 2025 (GLOBE NEWSWIRE) -- Alpha Liquid is pleased to announce the release of Episode 5 of the Alpha Liquid Podcast, featuring an in-depth conversation between host Matthew Mousa and Brody Adreon from TAO Times. This episode dives deep …
Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update
GlobeNewswire
·
May 14, 2025
ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing …
Le balado primé de CIRA « Qu’est-ce qui se passe avec l’Internet? » revient pour une troisième saison afin d’explorer l’impact de la mésinformation en ligne
GlobeNewswire
·
May 14, 2025
OTTAWA, Ontario, 14 mai 2025 (GLOBE NEWSWIRE) -- CIRA annonce aujourd’hui le lancement de la troisième saison de son balado primé, Qu’est-ce qui se passe avec l’Internet?, centré sur la montée de la mésinformation en ligne. De retour après avoir remporté …
CIRA’s award-winning ‘What’s up with the internet?’ podcast returns for its third season to investigate the impact of online misinformation
GlobeNewswire
·
May 14, 2025
OTTAWA, Ontario, May 14, 2025 (GLOBE NEWSWIRE) -- Today, CIRA announces the premiere of the third season of its award-winning podcast, What’s up with the internet? centred around the rise of online misinformation. Returning fresh off a win for ‘Best …
Redfin and Magnite Join Forces to Give Advertisers Priority Access to Audience Targeting Across the Homebuying Journey
GlobeNewswire
·
May 14, 2025
NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Redfin (NASDAQ: RDFN), the technology-powered real estate brokerage, has selected Magnite (NASDAQ: MGNI), the largest independent sell-side advertising company, as its preferred SSP to power data-driven deals. …
BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders
GlobeNewswire
·
May 14, 2025
VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company focused on the development of BETR-001, a non-hallucinogenic …
SailPoint to Announce Fiscal First Quarter 2026 Results on June 11, 2025
GlobeNewswire
·
May 14, 2025
AUSTIN, Texas, May 14, 2025 (GLOBE NEWSWIRE) -- SailPoint, Inc. (Nasdaq: SAIL), a leader in enterprise identity security, will report its fiscal first quarter 2026 financial results before the US markets open on Wednesday, June 11, 2025. SailPoint will …
aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
GlobeNewswire
·
May 14, 2025
Preclinical data demonstrate ATYR0101’s unique anti-fibrotic mechanism through interaction with LTBP-1. ATYR0101 to be showcased in oral presentation at the American Thoracic Society (ATS) 2025 Respiratory Innovation Summit. SAN DIEGO, May 14, 2025 (GLOBE …
Absorb Recognized as a Global Leader in Learning Technology by Fosway, Talented Learning and G2 in 2025
GlobeNewswire
·
May 14, 2025
CALGARY, Alberta, May 14, 2025 (GLOBE NEWSWIRE) -- Absorb Software, the leading global AI-driven learning platform provider, today announced it has been named a Core Leader with an Excelling Trajectory on the 2025 Fosway 9-Grid™ for Learning Systems, …
3Daughters Selects Connect Labs by Wexford - Baltimore for New Corporate Headquarters
GlobeNewswire
·
May 14, 2025
Access to Wexford Knowledge Community Platform Supports Creation of a Women’s Health Science Hub Presence within UMB BioPark Ecosystem and Provides Critical Connections for Growth BALTIMORE, May 14, 2025 (GLOBE NEWSWIRE) -- 3Daughters, Inc., a clinical …
Chapman University Releases International Housing Affordability Report Revealing None of the 95 Major Markets Affordable
GlobeNewswire
·
May 14, 2025
ORANGE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- For the first time in the report’s 21-year history, none of the 95 major housing markets analyzed across eight nations qualifies as “affordable.” This alarming statistic headlines the newly released 2025 …
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
GlobeNewswire
·
May 14, 2025
Pre-NDA Minutes from April 2, 2025, Meeting Received NDA Submission Planned this Summer KANSAS CITY, Kan., May 14, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) …
IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025
GlobeNewswire
·
May 14, 2025
Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB- …
Revolution Medicines Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating Daraxonrasib in Previously Treated Patients with RAS Mutant Non-Small Cell Lung Cancer
GlobeNewswire
·
May 14, 2025
REDWOOD CITY, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the first patient has been dosed …
Asia Broadband Completes Inaugural Shareholder Plant Tours of the New Gold and Silver Ore Processing Facility in Etzatlan, Mexico
GlobeNewswire
·
May 14, 2025
LAS VEGAS, May 14, 2025 (GLOBE NEWSWIRE) -- Asia Broadband Inc. (OTC: AABB) (“AABB” or the “Company”) is pleased to announce that the Company has now completed a week of shareholder tours of AABB’s new gold and silver ore processing facility in Etzatlan, …
Morae Acquires Information Governance Vendor Gimmal Broadening Its Technology-Based Solutions for Law Firms and Law Departments
GlobeNewswire
·
May 14, 2025
Houston, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Morae Global Corporation (“Morae”), the trusted, global leader in providing law firms, legal departments and compliance executives with solutions for managing their information lifecycle, today announced that …
Incannex Healthcare Inc. Provides Clinical Program Update on IHL-42X, an Oral Once-Daily Treatment for Obstructive Sleep Apnea (OSA)
GlobeNewswire
·
May 14, 2025
Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA. End-of-study follow-up assessments on track for completion by May 17, 2025. Topline results expected in July 2025. NEW YORK and MELBOURNE, …